HOME >> MEDICINE >> NEWS
Supertron raises $3.5 million in Series C Financing

Supertron Technologies Inc. ( www.supertron.com), a leading developer of next-generation solutions for high-performance preclinical and clinical Magnetic Resonance Imaging (MRI) coils and probes announced today successfully financing $3.5 million with Amphion Innovations PLC. Supertron is based in the Enterprise Development Center (EDC) (www.njit-edc.org) at New Jersey Institute of Technology (NJIT) (www.njit.edu).

The financing round was supposed to close at $3 million, but the financing increased to $3.5 million due to overwhelming investor demand. "We are excited by the market response to our offering and the validation of the strategic direction for our product and technology set," said C. Richard Hullihen, Supertron CEO.

Supertron's products significantly improve the imaging capabilities of MRI scanners. The cryogenically cooled products enhance image resolution, reduce scan time and lower cost through faster image acquisition. These factors ultimately result in earlier disease detection, faster drug development, and integrated and/or guided therapeutics. Its solutions are applicable in both high and low-field clinical and preclinical research environments imaging objects from molecules to man.

Supertron is also targeting emerging MRI research applications in the fields of molecular imaging, x-nuclei applications, functional MRI, image-guided therapeutics, and orthopedics imaging.

Earlier financing for Supertron included a per-reviewed $2 million grant from the Advanced Technology Program (ATP) at the National Institute of Standards and Technology (2003). The New Jersey Economic Development Authority (EDA) has also awarded the company $500,000 in springboard grants.

"We're indebted to our institutional ATP grant research partners at Brigham & Women's Hospital of Harvard Medical School and our ho
'"/>

Contact: Sheryl Weinstein
sheryl.m.weinstein@njit.edu
973-596-3436
New Jersey Institute of Technology
27-Jul-2006


Page: 1 2

Related medicine news :

1. Study raises new treatment possibilities for cognitive disorders
2. Having elevated risk factors in young adulthood raises risk of coronary calcium later on
3. Major discovery raises prospect of better patient care by improving platelet life span
4. Wartime raises stress, blood pressure rates in military offspring
5. Improved treatment raises medulloblastoma survival rate
6. Stopping medication too soon after receiving a drug-eluting stent raises risk of death
7. Selenium-protein deficiency raises prostate cancer risk
8. Childhood arthritis raises risk of broken bones
9. Rapid lung function decline raises risk of death and hospitalization
10. New research shows second-hand smoke raises diabetes risk
11. Obesity in middle age raises heart disease, diabetes risk in older age

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Supertron raises million Series Financing

(Date:11/27/2014)... (PRWEB) November 27, 2014 Now that ... season has officially launched, Emassagechair.com has announced ... Monday Discount Event. , Negotiating on behalf of ... top massage chair brands, Emassagechair.com has generated significant buzz ... deals and biggest discounts yet. , Shoppers are excited ...
(Date:11/27/2014)... 27, 2014 VogueQueen.com is making every ... ladies across the world. As the premier online supplier ... is proud to release a huge selection of sexy ... outfits, it is also providing many beautiful styles in ... gowns at discounted prices. , “VogueQueen.com hopes to ...
(Date:11/27/2014)... 27, 2014 Developers and plugin specialist of ... entitled ProPip, taking FCPX to the next level. , “ProPip ... a few clicks of a mouse,” said Christina Austin, CEO ... our users will appreciate.” , With ProPip users can show ... possibilities truly endless. ProPip is great for commentaries, news casting, ...
(Date:11/27/2014)... HealthPostures, a leading national designer ... announced that it has entered into a new ... will put HealthPostures' products into central Indiana’s premiere ... to having its products sold through Commercial Office ... with the business decision makers in the Indianapolis ...
(Date:11/27/2014)... At The Little Gym, we know ... as no surprise when a recent study confirmed that ... The Journal of Pediatrics found that “Promoting ... during the school years may be important not only ... study monitored two groups of children; those that were ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
(Date:11/26/2014)... 2014  Array BioPharma Inc. (Nasdaq: ... Chief Executive Officer, Ron Squarer , ... The public is welcome to participate in ... BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray 2014 ... Time Location: Palace Hotel, New York CityEvent:Oppenheimer ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
(Date:11/26/2014)... and HERZLIYA PITUACH, Israel, Nov. 25, 2014 ... Company"), a clinical stage biopharmaceutical company that engages ... for the treatment of inflammatory diseases and cancer, ... underwritten public offering of 3,450,000 units, with each ... common stock, par value $0.0001 per share, and ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
Cached News: